INTRODUCTION
In the last decade zebrafish has emerged as a novel model to study vertebrate hematopoiesis. Similar to mammals, zebrafish have sequential waves of hematopoiesis: the primitive and the definitive wave, that occurs in distinct intra-embrionic sites. The zebrafish primitive wave initiates at the 1-3 somite stage. This process is comparable to mammalian primitive hematopoiesis, which takes place in the yolk sac and it is characterized by the presence of primitive hematopoietic and endothelial cells (ECs) that make up a rudimentary circulatory system. 1 The multilineage self-renewing hematopoietic stem cells (HSCs) arise from specialized vascular ECs, the hemogenic endothelium, in the aorta gonads mesonephros region during the definitive wave of hematopoiesis. 2, 3 Before HSCs appear, committed erythroid/ myeloid progenitors (EMPs) emerge in the yolk sac of mammals, wheras zebrafish EMPs arise between 24 and 30hpf in the posterior blood island. 4 Studies in the mouse embryos show that EMPs and HSCs have similar cell-surface markers, differing only in their differentiation and self-renewal potentials; in zebrafish the activation of Notch signaling characterized the HSCs. 5, 6 In zebrafish, the HSCs originated from the hemogenic endothelium seed the posterior blood island/caudal hematopoietic tissue (CHT) 7 before reaching the kidney marrow (KM) and thymus, whereas in mammals hematopoiesis continues in the fetal liver and placenta before HSCs populate the spleen, thymus and finally the bone marrow. 8 Starting from 4dpf and during the whole adult life, the zebrafish KM represents the definitive site of hematopoiesis.
Given the similarities in ontogeny and development of the hematopoietic system, malignant hematological diseases have been modeled in zebrafish through transgenic expression of human oncogenes. Several 'oncogenes' involved in myeloid leukemia have been transiently overexpressed in zebrafish embryos. These include K-RAS, 9 the fusion oncogene AML-ETO (RUNX1-CBF2T1), 10 cytoplasmic NPM1 mutant (NPMc þ ) 11 and fusion oncogene NUP98-HOXA. 12 Despite the first encouraging results these models failed to fully recapitulate the pathological features of human myeloid malignancies. 13, 14 The critical point seems to be the ability to target the right cells in the hematopoietic lineage, and the highest success rate has been obtained through random targeting, perhaps due to accidental hits of a cell high-in-the-hierarchy of the hematopoietic lineage. 13, 15, 16 The v-Ha-ras Harvey rat sarcoma viral oncogene, HRAS (gene id: 3266) carrying the activating mutation G12V is one of the most frequently mutated cancer gene in human malignancies, including myeloproliferative disorders (Cancer Genome Project in the Catalogue Of Somatic Mutations In Cancer (COSMIC) (www.sanger.ac.uk/genetics/CGP/Census/). 1 Here, we used the promoter of the Friend leukemia virus integration 1 (fli1) gene, an ETS transcription factor required for ECs development 17 to drive the expression of oncogenic human HRAS to early ECs, including the hemogenic endothelium that give rise to definitive HSCs and observed the development of hematopoietic disorders similar to those occurring in myeloproliferative neoplasms in a few weeks.
MATERIALS AND METHODS

Zebrafish strains and maintenance
Zebrafish transgenic lines were maintained as previously described. 18 Strains included: tg(fli. ; tg(UAS:myc-Notch1a-intra) kca3 , 21 tg(TP1bglob:eGFP) um14 , 22 tg(UAS:GFP); tg(c-myb:EGFP) zf169 and tg la223 also known as tg(CD41:GFP).
DNA microinjection
For mosaic expression, DNA plasmids were injected into 1-cell stage embryos. Tg(fli. 1:Gal4FF ubs3 ;UAS:RFP) rk8 embryos were coinjected with 2 nl of plasmid containing UAS-egfp-HRASV12 (15 ng/ml) and Tol2 mRNA (35 ng/ml). 24 To study the effect of Notch signaling on RAS, tg(fli. 1:Gal4FF ubs3 ; UAS:RFP)
rk8
; tg(TP1bglob:eGFP) um14 double transgenic embryos were injected with 2 nl of pT2M:H2B-CFP-UAS-HRASV12 (30 ng/ml) and Tol2 mRNA.
A plasmid pDest4nrUAS-YFP-HRAS (30 ng/ml) and Tol2 mRNA mix were used for control injections. After injection, embryos with GFP þ cell clones were selected for live imaging at different stages of development.
Histology and immunofluorescence
Five dpf larva and juvenile fish and age-matched control were killed by anesthetic overdose and fixed for 2 h at room temperature in 4% paraformaldehyde. After overnight incubation in sucrose, sample were transferred to optimum cutting temperature (OCT; Sakura Finetek, Torrance, CA, USA). Cryostat sections (16 mm thick) were air-dried and incubated overnight with rabbit polyclonal anti L-plastin, 25 (diluted 1:500) and mouse anti eGFP (1:1000) antisera. Secondary antibodies conjugated with Alexa 488, Alexa 546 and Alexa 633 were from Molecular Probes (Carlsbad, CA, USA). 4 0 ,6-Diamidino-2-phenylindole, DAPI (1:10 000) counter stain was carried out on all sections.
Analysis of human leukemia data set
Microarray Innovation in Leukemia data set (GSE13159) 26 was used to analyse gene expression of the human orthologues of the zebrafish genes (dab2, mrc1, stabilin2, parvin-a, gpr182). Briefly the average expression values of every single microarray probe for each subgroup of myeloid leukemia and myelodysplastic syndrome samples were compared with healthy control bone marrow (Student's t-test).
See Supplementary Materials and Methods for further details.
RESULTS
Targeting oncogenic RAS to fli1 þ cells induces proliferation of the CHT and increase of leukocyte number We used the UAS-Gal4 binary system 21 to study the effects of oncogenic RAS expression on cells of the hemogenic endothelium in zebrafish. A transgenic line, the tg(fli1ep:GAL4FF) ubs3 that drives Gal4FF 27 expression in the early endothelial progenitors 19 was crossed with the reporter line tg(UAS:eGFP) (Figure 1a ) to obtain a progeny characterized by GFP expression in the vasculature and in hemogenic endothelium (Figures 1a and b) . Expression of the reporter gene started at 12 somites (12s) although expression of the fli1 gene starts much earlier 28 (Supplementary Figure S1 ). This delay is probably due to the promoter used that may not recapitulate the timing of the endogenous fli1 expression, or to the time required to accumulate enough Gal4 to activate the reporter. 29 At 30hpf the expression of eGFP in the double transgenic line fully recapitulates the expression of fli1 30 ( Figure 1b ).
Then we crossed tg(fli1ep:GAL4FF) ubs3 fish with the tg (UAS:egfp-H-RASV12) io6 line 31 to evaluate whether fli-Gal4FF cells were transformed by the oncogene (Figures 1e-f) . We observed that larvae expressing oncogenic RAS under the control of the fli1 promoter developed an expanded CHT and showed hyperproliferation of the hematopoietic cells starting from 27hpf ( Figures  1c-m) . To simplify the nomenclature we will refer to the zebrafish from this cross as fli-RAS, whereas we indicate the controls, tg(fli1ep:GAL4FF) ubs3 ; tg(UAS:eGFP), as fli-GFP zebrafish. In addition to the expansion of the CHT and the hyperproliferation of the hematopoietic tissue, fli-RAS larvae developed a vascular phenotype characterized by the formation of cardiac and caudal edema (Supplementary Figures S2D-F) .
We used BrdU to label proliferating hematopoietic cells in the CHT at 30hpf. All CHT cells were labeled in fli-RAS larvae following exposure to BrdU at 30hpf (Figure 1h ), whereas fewer CHT cells were BrdU labeled in control larva (Figure 1d ). We also used phospohistone 3 (PH3) immunostaining to label cells in M phase and quantify them (Figures 1i-m) . We analysed 380 (in 5 fli-GFP) and 630 (in 5 fli-RAS) GFP þ CHT cells. We found that in controls 13.9% ± 0.83 cells were phospohistone 3 positive (mean 5.25±0.95 per larva), whereas in fli-RAS 23.1%±2.75 GFP þ CHT cells were marked by phospohistone 3 staining (Figure 1m ).
To make sure that the cells that over proliferate in the CHT belonged to the hematopoietic lineage, we carried out in situ hybridization for the hematopoietic cell marker, c-myb. 4 We found that the expanded CHT of the fli:RAS larvae expressed c-myb and that some of the c-myb þ cells were also positive for phospohistone 3 (Figures 1n-q) . Thus, the cells overproliferating in the CHT of fli-RAS embryos are hematopoietic cells expressing c-myb.
To analyse the expression of hematopoietic markers we performed quantitative reverse transcription PCR (qRT-PCR). Three dpf fli-RAS larvae showed an increase of expression of myelo-erythroid marker genes (pu.1, gata-1, mpx, c-mpl) associated with an increase of hemogenic precursor genes (lmo2 and scl), whereas the genes restricted to the HSC compartment (c-myb, runx.1) were unchanged compared with age-matched fli-GFP controls (Figures 2a and b) . We also stained larvae with an antibody against l-plastin, which labels all leukocytes 25 and observed a marked increase in l-plastin positive cells in the whole fli-RAS larva at 2dpf compared with controls (Figures 2d and f) . We found a mean number of 166 ± 15 l-plastin þ cell/larva in controls and 255 ± 9 l-plastin þ cells/larva in fli-RAS.
To investigate whether the increase number of leukocytes was due to an inflammatory response, we measured the levels of the pro-inflammatory gene mmp-9 in the whole larvae, and found that the levels were similar between controls and fli-RAS larvae (Figure 2c ), thus ruling out inflammation as a cause of the increase of l-plastin þ leukocytes.
Cytology shows abnormal blood cells In order to better characterize the phenotype of fli-RAS larvae we evaluated the morphology of peripheral blood cells after May Grunwald-Giemsa staining. Specimens from 12 fli-RAS larvae (Figures 2j-o) compared with peripheral blood smears from 12 fli-GFP larvae (Figures 2g-i) contained a larger number of immature, spherical red blood cells (immature RBCs), basophilic elements resembling erythroid precursors (asterisks in Figure 2j ) and binucleated RBCs (arrow, Figure 2k ). We compared erythrocyte morphology of 24 5dpf fli-RAS with age-matched controls and observed a statistically different Nucleus:Cytoplasm (N:C) ratio 32 suggesting that RAS-induced delayed erythroid maturation (Figures 2p-q) . In the peripheral blood of the pathological larvae, we also observed a population of medium sized immature cells, with a high N:C ratio, evenly distributed chromatin and basophilic cytoplasm with no granules (Figure 2o , arrowheads). These cells are very rare in control specimens. Moreover, we found several Oncogenic transformation of hemogenic endothelium E Alghisi et al macrophages surrounding other hematopoietic cells; some of these macrophages showed cellular debris in cytoplasmic vesicles, suggesting a phagocytic activity (arrow in Figure 2n ). The lymphoid population was unchanged showing normal cyto-morphological features, (small cells with purple nucleus, arrow in Figure 2m ), although we quantified a slight reduction in their number, in sharp contrast with the increase of other leukocytes (Figure 2p) . Thus, cytological analysis of the blood of fli-RAS larvae show the prominent presence of immature and abnormal blood cells.
RAS expressing cells colonize the kidney and give rise to abnormal definitive hematopoiesis To overcome the problem of early lethality and obtain further confirmation that the expression of the RAS oncogene driven by the fli1 promoter induced abnormal proliferation of the myelo-erythroid compartment, we mosaically expressed the GFP-RAS plasmid in the tg(fli1ep:GAL4FF) ubs3 line (Figure 3a ). At 30hpf we observed sparse GFP-RAS þ cells in the endothelium and in the CHT of injected larva (Figures 3b and c) . Oncogene expressing cells in CHT were round shaped, cells resembling hematopoietic precursors (Figure 3d ). At 3dpf, 30% of the RAS injected larvae exhibited increase of the CHT without other developmental defects (Supplementary Figures S2G-I ). Moreover, they reached juvenile stages and showed an increased survival compared with the fli:RAS double transgenic line (Supplementary Figure S2J) . In controls, we injected a UAS:YFP-HRAS plasmid, which encodes for non-oncogenic RAS tagged with YFP (Supplementary Figure S3C) . Although the injected controls showed mosaic YFP-HRAS expression only in ECs (Supplementary Figure S3B) , larvae with mosaic oncogenic RAS expression showed an enlarged CHT similar to fli:RAS larvae (Supplementary Figure S2I) . To analyse the cells in the expanded CHT of fli inj RAS larvae, we crossed the fli-Gal4FF line and the tg( À 6.0itga2b:EGFP) la2 line (also known as tg(CD41:GFP)), and injected embryos from these crosses with pT2M:H2B-CFP-UAS-HRASV12, a plasmid encoding for oncogenic RAS and histone2B-CFP under a bidirectional UAS sequence (shortened in H2B:UAS:CFP-RAS, Figure 3e ). In this way, cells that express RAS are marked by a blue nucleus, making it possible to assess coexistence with CD41-GFP, which marks hematopoietic cells. 23 We also exposed these larvae to BrdU to clarify whether dividing cells in the CHT were CD41-GFP þ . We found that the RAS-expanded CHT contained a large number of CD41:GFP þ hematopoietic cells (Figures 3f and j To test whether the fli-Gal4FF line is able to drive the expression of Gal4 in HSCs we made use of double transgenic tg(fli1ep: GAL4FF ubs3 ; UAS:KAEDE rk8 ) fish ( Figure 4a ). These fish express the photoconvertable protein Kaede in fli-Gal4FF cells. In order to demonstrate that fli-Gal4FF cells can give rise to hematopoietic cells we used UV-photoconverted Kaede from green to red at 32-33hpf in parts of the dorsal aorta (Figure 4b) , which has been shown to give rise to HSCs starting around 36hpf. 3, 33 At 5dpf, the site of UV exposure was still demarcated by red Kaede in the vasculature (Figure 4c ). In addition we observed red cells in the CHT (Figure 4d ) and in definitive hematopoietic sites such as the thymus (Figures 4e-g ) and the pronephros (Figures 4e, h-i ; UAS:KAEDE rk8 ) with fish from the tg(c-myb:EGFP) zf169 line that labels HSCs with GFP. 23 We photoconverted Kaede from green to red, resulting in GFPcmyb/red Kaede fli-Gal4FF cells. In time-lapse movies we observed that these Kaede-red/c-myb þ cells showed the typical behavior of HSCs and budded off the ventral wall of the dorsal aorta (Supplementary movie 1) .
In further cell tracing experiments we injected double transgenic fli-Gal4FF/UAS:Kaede with H2B-CFP:UAS:RAS to follow RAS expressing cells with a different fluorescent marker (Figure 4j ). First, Kaede was converted specifically in the aorta gonads mesonephros region of triple transgenic fish at 30-32hpf (Figures 4k-l) to label aorta gonads mesonephros derived cells with red Kaede. Then, we recorded images of these Kaedeconverted fish at 73hpf: 9 out of 10 fish showed cells labeled with red Kaede in the CHT region and in anterior regions especially on the yolk (boxed in Figure 4m ). These cells also showed expression of H2B-CFP, which demarcates expression of the RAS oncogene (Figure 4n-u) . This indicates that at least a subpopulation of RAS expressing cells is derived from the endothelium of the aorta gonads mesonephros region, which was shown to give rise to HSCs.
To be able to investigate the behavior of RAS expressing ECs in more detail we recorded time-lapse movies of fli-Gal4FF 48hpf larvae injected with UAS-GFP-RAS plasmid. We observed the generation of hematopoietic precursors from the hemogenic endothelium and their subsequent cell division (Supplementary movie 2).
As mosaic larvae can survive to juvenile stages (Supplementary Figure S2J) , we carried out an analysis of the definitive hematopoietic compartment in the KM and peripheral blood of 9dpf injected juveniles. In sections, immunostained KM cells were identified based on their localization, shape and l-plastin staining. While all the YFP-wt-RAS expressing cells in the kidney were part of the vascular system (Supplementary Figures S3G and S3H ), Figures S3I and S3J ) appeared as l-plastin monocytes, according to their shape. In crosses between the fli-Gal4FF and the tg(CD41:GFP) lines, injections with H2BCFP-UAS-RAS plasmid marked cells in the kidney that also express CD41:GFP (Supplementary Figure S3M) and l-plastin ( Supplementary Figures S3N and S3O ).
GFP:RAS positive cells (Supplementary
Cytological analysis of KM cytospin preparations from 5 fli-GFP juveniles showed the normal complement of hematological cells (Figure 5a ), whereas in Ras-injected fli-Gal4FF juveniles we found that 3 out of 9 had clearly abnormal number of myeloid progenitors (mp) in different stages of maturation. We counted a mean number of 300 cells per animal (Figure 5b ) and classified mp in three different types, according to the maturation stage (mp1 less mature, mp3 more mature, Figure 5a ). In the mosaic RAS fish showing the milder phenotype (RAS 1, Figure 5d ) mature mp3 were approximately double than in controls (Figure 5c) , with an over representation of mp3 also in the blood (Figure 5h) . In a second affected mosaic RAS fish (RAS 7, Figures 5e and i), which had a small kidney, we found an increase of all mp, which were also overrepresented in the peripheral blood at the expenses of mature myeloid cells (Figure 5i) . The most severely affected mosaic RAS fish was a 3-week-old juvenile (RAS 4), without mature hematopoietic cells in the KM where only clusters of immature myeloid blasts (mp1) made up of 460% of the whole population of hematopoietic cells (Figures 5f and j) .
Thus, mosaic expression of the oncogene in the fli:Gal4FF larvae and juveniles provided evidence that oncogenic RAS driven by the fli1 promoter was able to severely affect definitive hematopoietic cells that populated the KM in addition to the CHT as reported in the previous section. This resulted in the presence of abnormal myeloid cells in the peripheral blood of mosaic juvenile fish. Therefore, we concluded that RAS expressing hemogenic ECs also gave rise to HSCs that populated the CHT and the KM and had the potentials to generate abnormal clones similar to those found in primary or secondary acute leukemia where immature blast cells progressively infiltrate the bone marrow and lastly circulate into the peripheral blood. These blasts cells are usually medium sized cells, characterized by a round shape nucleus and a mild basophilic cytoplasm with thin granules and resemble those found in this zebrafish model. 34 RAS expression in hemogenic progenitors represses NOTCH activation Given the involvement of the Notch pathway in the regulation of HSCs production and endothelial differentiation (see Discussion), we sought to evaluate Notch pathway activation in RAS-induced transformation of CHT and hemogenic endothelium through an analysis of the expression of Notch regulated genes. 
Oncogenic transformation of hemogenic endothelium E Alghisi et al
The expression of notch1, notch3 and her6, quantified through qPCR, was remarkably lower in 3dpf fli-RAS larvae compared with fli-GFP control larvae (Figure 6a ). Furthermore, we sorted GFP-RAS positive cells and analyzed her6 expression compared with sorted control fli-GFP positive cells. The expression of her6 was lower in GFP-RAS sorted cells compared with controls (Figure 6b) . In order to evaluate Notch activity in vivo we used a reporter line, tg(TP1bglob:eGFP). 22 In this line referred as TPbglob, the expression -binding sites. The TP1 element has been shown to be Notch responsive in both mammalian and zebrafish cells. 22, 36 eGFP expression in the TPbglob line is observed in tissues known to be Notch responsive such as the developing central nervous system, the vasculature, the definitive hematopoietic compartment, liver, intestine and pancreas. 22 To clarify whether fli-Gal4FF cells expressing RAS downregulate the Notch pathway, we induced somatic expression of oncogenic RAS through the injection of the H2B:UAS:CFP-RAS plasmid in embryos double transgenic for fli-Gal4FF and TPbglob ( Figure 6c ). As expected, fliGal4FF;TPbglob injected embryos exhibited the accumulation of H2B-CFP-RAS positive hematopoietic cells in the CHT (Figures 6f  and g ), whereas control embryos showed H2B-CFP expression mainly in ECs (Figures 6d and e) . The H2B-CFP positive ECs were GFP labeled indicating the activation of the Notch pathway (insets, Figures 6d and e) as previously reported. 37 By contrast H2B-CFP:RAS Figure 4 . See next page for caption.
Oncogenic transformation of hemogenic endothelium E Alghisi et al expressing cells were GFP negative (inset Figures 6f and g) , demonstrating that the expression of the oncogene-induced selective inhibition of the Notch pathway (Figure 6h ). To investigate whether the downregulation of the Notch pathway in the hemogenic endothelium is a necessary event in RAS-induced myelo-erythoid proliferation, we attempted to rescue the latter phenotype by overexpressing an activated form of Notch (the cleaved notch intracellular domain, or NOTCH intra or NICD) in the ECs together with RAS, using the tg(UAS:NICD) kca3 transgenic line. 21 Crosses between a double transgenic line UAS:RAS/UAS:NICD with the driver line, fli-Gal4FF resulted in an attenuation of CHT expansion, and injection of UAS:RAS in fli-NICD embryos did not cause the CHT phenotype in 23 out of 29 embryos (as opposed to 100% of CHT phenotype following injection of UAS:RAS in fli:Gal4FF embryos), suggesting that increasing NOTCH activity in fli:RAS expressing cells reduces the proliferation of CHT progenitors (Supplementary Figures S4A-E) . To gain insights on the mechanisms though which activated NOTCH may prevent the hyper proliferation of CHT cells induced by RAS we analysed apoptotic cell death using TUNEL at 48hpf (Supplementary Figures S4F-J) . We found that the number of TUNEL þ CHT cells was 43±16 in fli:RAS, 38±8 in fli-injected RAS and 70±29 in fli:NICD injected RAS larvae,while it was negligible (1 to null) in controls. This analysis suggests that activated NOTCH may promote apoptosis in the presence of oncogenic RAS and therefore prevent the increase in size and the proliferation of RAS expressing CHT cells.
QPCR analysis of hematopoietic gene expression in fli:ras, fli:NICD and fli:NICD injected with UAS:egfp-HRASV12 plasmid showed that the increase in the expression of lmo2 and scl induced by RAS (see Figure 2k) was not taking place in fli:NICD larvae (Figure 6i ), thus suggesting that forced activation of the Notch pathway in hematopoietic cells may prevent most of the effects of RAS on CHT cells.
RNA-Sequencing reveals novel candidates in myelo-erythroid disorders In order to discover new genes involved in RAS effects on endothelial progenitors we performed RNA-sequencing analysis.
We analyse the whole transcriptome of 3dpf fli-RAS and fli:NICD larvae (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc= GSE41988). We focused on transcripts that were upregulated in fli-RAS and downregulated in fli-NICD larvae (Figures 7a and b) . Only genes that displayed significant differential expression (cutoff: log2 FC 42) for both parameters (Supplementary Table I) were considered further. This double filtering procedure allowed us to identify 23 differentially expressed genes ( Figure 7b ). As only 12 of the 23 identified transcripts corresponded to known genes, we carried out qPCR validation for the 12 candidates shown in Figure 7c .
Validation through qPCR analysis in 3dpf fli-RAS and fli-NICD larvae showed that stabilin2, parvin-a, mrc1, dab2 and gpr182 were significantly upregulated by RAS and with the exception of parvina, they were also concomitantly downregulated by activated NOTCH in all the tested pools of transgenic larvae (Figure 7c ). The five genes are involved in cell adhesion and cytoskeleton organization (parvin-a) or are markers of ECs in the forming vasculature (dab2, stabilin2, gpr182) or markers of macrophages (mrc1). As these genes have not been associated with myeloproliferative disorders before, we searched data sets of gene expression from leukemic samples to evaluate their relevance to different forms of myeloproliferative disease. We looked at the Microarray Innovations in Leukemia (MILE) study, where 748 different subgroups of myeloid leukemia and myelodisplastic syndrome bone marrow samples were analysed using commercially available whole-genome microarray. 26 The analysis revealed a significant increase of MRC1 expression in myelodisplastic syndrome and acute myeloid leukemia with complex karyotype, whereas DAB2 expression was increased in all leukemia samples characterized by cytogenetic alterations. Intriguingly the expression of STAB2 was found diminished in all leukemia bone marrow compared with controls. Finally, GPR182 and PARVA expression were not significantly changed (Figure 7d , Supplementary Table II) .
DISCUSSION
In this study, we have established a zebrafish transgenic model for the study of myeloproliferative neoplasms based on the expression of an oncogene driven by the fli1 promoter, which is active in ECs including those of the hemogenic endothelium. We show that expression of RAS in fli-Ga4FF cells induces hematopoietic defects that affects two sites of definitive hematopoiesis in zebrafish: CHT and KM. The abnormal hematopoiesis is characterized by increased proliferation of hematopoietic progenitors and delays in myelo-erythroid maturation as revealed by cytological analysis of the hematopoietic tissue and peripheral blood. We further used the model to identify the repression of Notch signaling as a necessary event in RAS-induced increase of myelo-erythroid progenitor cells in the CHT.
The fli1 promoter used in this study is known to drive the expression of reporter genes, in different cell types, making it challenging to pinpoint the fli1 þ cell population(s) responsible for the effects of RAS described here. Besides cells of the primitive wave of hematopoiesis, it also drives expression of the oncogene in the hemogenic endothelium. 33 On the basis of experiments of lineage tracing, on the presence of abnormal myelopoiesis in the KM and on the retrieval of myeloid blasts in the peripheral blood of juveniles, our data suggest that the long-lasting hematopoietic disorders observed in RAS transgenic juvenile fish is due to RAS expression in a definitive hematopoietic population. To visualize these events, we used mosaic expression of the oncogene in the fli-Gal4FF line, an approach that mimics sporadic occurrence of mutations in somatic cells, one of the most frequent causes of cancer in humans. Thus, although there may be more than one fli-Gal4FF populations involved, the presence of abnormal mp in Note that the percentage of lymphocytes, erythrocytes, erythroblasts and platelets is highly variable as it depends on the amount of blood retained by the specimens. Abnormal RAS specimens are underlined. (c-j) May-Grunwald-Giemsa staining of KM cytospins (c, d, e, f, j) and peripheral blood (g, h, i) of 3-4-week-old control fli-Gal4FF and mosaic fli-RAS zebrafish, as indicated. In controls KM preparations all common hematopoietic cell types can be found, while peripheral blood (g) contains erithrocytes, rare mp (arrow), rare macrophages (asterisk) and lymphocytes (not shown). In mosaic fli-RAS fish no.1 (d-h) a large number of mp, mostly type 3 (arrows) and type 2 (arrowhead) were found in the KM (d) and peripheral blood (h). In mosaic fli-RAS fish no. 4 (e-i), the KM was atrophic and the few cells present were mostly mp type 1 (red arrow) and 3 (arrows). In the blood of this individual we found a large number of mp type 3 (arrows in i) and thrombocytes (pink flat cells). In mosaic fli-RAS fish no. 7 (f, j) KM cytospins were largely composed of aggregates of mp type 1 (small round cells with very basophilic nuclei and small cytoplasm, red arrows). In these clusters mp type 2 (arrowheads) were also found. Occasionally, other cell types were present together with a few macrophages (asterisk in f, j). Calibration bar 10 mm.
the KM and peripheral blood indicates the involvement of HSCs originated from the hemogenic endothelium and suggest that hemogenic ECs may function as leukemia initiating cells. 1, 34 Although the hemogenic endothelium is known to give rise to multipotent HSCs, we did not find evidence of perturbation of the lymphoid lineage. The observation that lymphocytes show no significant alterations in number or stage of maturation may suggest that RAS has scarce ability to transform lymphocytes (that is, its effectors are disabled or its expression is not maintained) or their progenitors. Alternatively the fli1 promoter that drives RAS expression in this model may continue to be expressed/functional only in a bipotential EMP. EMPs have been described in all vertebrates 14 as a transient population, preceeding the long-lived, self-renewing HSCs and generated in locations that only transiently represent sites of definitive hematopoiesis. However, a recent report in mouse show evidence of two distinct populations of hemogenic ECs, one giving rise to EMPs and the other generating HSCs. 38 The mouse data indicate that EMP and HSC formation can be uncoupled, and that the expression of Ly6a specifically marks a subset of hemogenic ECs that are destined to produce HSCs. Whether there are different populations of hemogenic endothelium differing for their location, commitment and molecular program in zebrafish is not known. Interestingly, studies in zebrafish suggest that EMPs are generated in the CHT, and unlike HSCs, do not require Notch signaling for their differentiation. 6 The fact that expression of oncogenic RAS under a fli1 promoter does not lead to overt transformation of ECs, but only of a subpopulation of hemogenic ECs, suggest that additional factors may be necessary to make ECs susceptible to transformation, although the expression of the oncogene is causing blood vessel abnormalities, which have not been investigated here, but are probably linked to a fate switch.
The second important finding of this study is that, mechanistically the effect of RAS on hematopoietic cells is linked to downregulation of Notch signaling. Notch signaling is used repeatedly and with different outcomes in the lineage of mesodermal cells that leads to the production of endothelial and hematopoietic cells (the so-called hemangioblasts, 39 ). For example, in the cell fate switch between the endothelial and hematopoietic lineages in the mesoderm, inhibition of Notch signaling promotes endothelial versus hematopoietic fate in zebrafish. 40 Next, Notch signaling is required for HSCs specification/survival and/or self-renewal but not for EMPs differentiation, as EMPs isolated from mindbomb mutants (lacking functional Notch ligands) can differentiate normally in culture. 4 This leads us to believe that the inhibition of Notch signaling induced by oncogenic RAS in the hemogenic endothelium favors the generation of EMPs (or mimicks a developmental switch between HSC and EMP that may take place as soon as hemogenic ECs are generated from dorsal aorta and leads to two different fates, either migrating to the CHT or to the KM). A model depicting this switch is presented in Figure 8 .
We find intriguing that the expression of a reporter driven by the fli1 promoter is maintained in RAS expressing (but not in control) hematopoietic cells. Indeed, expression of fli1 is switched off in hemogenic ECs soon after their generation, 41 and HSCs in the KM do not express fli1, whereas EMPs in the CHT show persistent expression of fli1. 42 One explanation is that the expression of RAS blocks HSC differentiation so that they maintain their immature signature; another explanation is that RAS promotes immortalization of EMPs and that they are responsible for the myeloproliferative disorders described in this model. More studies are required to clarify this point.
Finally, what is the significance of the gene expression signature obtained through analysis of fli-RAS and fli-NICD larvae? Although only 4 of the 12 genes were validated by qPCR as concomitantly upregulated in fli-RAS and downregulated in fli-NICD, all the other genes were either upregulated in fli-RAS or downregulated in fli-NICD. Therefore, it would be interesting to test their role in fate switch or maintenance in the hematopoietic lineage. Two of these genes, MRC1and DAB2 showed an increase in expression in leukemia samples, suggesting that they may be more than just markers. Indeed, the genes signature may underlie the involvement of specific pathways (RAS activation, Notch inhibition) or the cellular origin of the disease (hemogenic endothelium, EMP or HSC).
In summary, this study has provided evidence for a novel mechanism of leukemogenesis, through transformation of hemogenic ECs, novel signaling events (downregulation of Notch signaling) and novel candidate genes in a vertebrate model. Figure 8 . Model depicting the effects of RAS on the hemogenic endothelium. Non tranformed hemogenic ECs (yellow circles) bud off the wall of the dorsal aorta and upregulate NOTCH activity ( þ NOTCH) to generate self-renewing HSCs. HSCs then give rise to common myeloid progenitors (CMPs) in the KM and common lymphoid progenitors (CLPs) in other locations. When hemogenic ECs express oncogenic RAS (green circles), they downregulate NOTCH (-NOTCH) and form predominatly erythro-myeloid progenitors (EMPs), which give rise to erythrocytes and myeloid cells in the CHT. Results from this study suggest that the oncogene may immortalize EMPs giving them the ability to self-renew (revolving arrow with question mark) and migrate to the KM (arrow with question mark), resulting in a myeloproliferative disorder. An open question is whether downregulation of NOTCH is linked to the EMP fate also in the absence of RAS (gray cloud).
